Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DUT | P33316 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2633190 | 0.83 | TSHR (0.39) | KMT2AMAPT | |
| SCHEMBL2628022 | 0.79 | CNR2 (0.39) | IDO1TDO2 | |
| SCHEMBL2633216 | 0.77 | SLC7A5 (0.40) | OPRM1OPRD1OPRK1OPRL1AOC3 | |
| SCHEMBL29061977 | 0.77 | AOC3 (0.40) | AOC3KMT2AMAPTIDO1TDO2 | |
| SCHEMBL954467 | 0.77 | AOC3 (0.40) | AOC3KMT2AMAPTIDO1TDO2 | |
| SCHEMBL16854730 | 0.72 | OPRM1 (0.40) | OPRM1OPRD1OPRK1OPRL1AOC3 | |
| SCHEMBL10370985 | 0.71 | CNR2 (0.43) | OPRM1OPRL1KMT2AMAPTIDO1 | |
| SCHEMBL28748834 | 0.70 | SLC6A2 (0.41) | AOC3SLC7A5KMT2AIDO1TDO2 | |
| SCHEMBL28782703 | 0.69 | MAOB (0.44) | GAAMAPTSLC6A4 | |
| SCHEMBL11994155 | 0.69 | CYP19A1 (0.48) | OPRM1OPRD1OPRK1OPRL1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357809-B2 | Acyclic IKur inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120094983-A1 | ACYCLIC IKUR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| US-7915410-B2 | Acyclic IKur inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-20070082909-A1 | Acyclic Ikur inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-12 | — | — | US | disclosed |
| WO-2007030582-A2 | ACYCLIC IKUR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082909-A1 | Acyclic Ikur inhibitors | KCNH2, KCNJ2, KCNH3 | OPRM1 549/4885OPRD1 233/4885OPRK1 102/4885 |
| US-20120094983-A1 | ACYCLIC IKUR INHIBITORS | KCNH2, KCNJ2, KCNH3 | OPRM1 549/4885OPRD1 233/4885OPRK1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.